Diabetes

June 20, 2019

Mechanistic insights into how Ciliary neurotrophic factor (CNTF) aids in control of body weight, energy homeostasis and TIIDM:  CNTF increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 20/June/2019, 10.52 pm

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour […]
June 20, 2019

Mechanistic insights into how Liraglutide aids in remission of Diabetes: Liraglutide (brand name: Victoza, Saxenda and others), a  drug used in the treatment of type II diabetes, inhibits Amysin expression, increases insulin secretion, and decreases the risk of hyperglycemia, via downregulation of  Sox4 and its target gene Amysin,  20/June/2019, 7.13 am

Introduction: What they say  Nobel laureate [ in Physiology/Medicine in 1975] Prof. David Baltimore and his research team, from California Institute of Technology, California, USA, had reported in the September 14, […]
June 10, 2019

A coconut way to say no to weight gain and Diabetes: Coconut oil-derived compound Lauric acid plays a significant role in body weight control, energy homeostasis and TIIDM: Lauric acid (LA-C12) or Dodecanoic acid (DA), one of the main components (48-52%) of coconut oil,  decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 10/June/2019, 11.14 pm

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by […]
June 4, 2019

Curing diabetes with Liraglutide: Liraglutide-based therapy for TIIDM and obesity-associated metabolic deficits: Liraglutide (trade name:Victoza, Saxenda), a glucagon-like peptide-1 agonist used in the treatment of diabetes, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, decreases TXNIP expression, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 04/June/2019, 12.14 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent […]